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During the last decade, a variety of monoclonal antibodies have been developed and used
as molecular targeting drugs in medical therapies. Although antibody drugs tend to have
intense pharmacological activities and negligible side effects, several issues in their devel-
opment and prescription remain to be resolved. Synthetic peptides with affinities and speci-
ficities for a desired target have received significant attention as alternatives to antibodies.
In vitro display technologies are powerful methods for the selection of such peptides from
combinatorial peptide libraries. Various types of peptide binders are being selected with
such technologies for use in a wide range of fields from bioscience to medicine. This mini
review article focuses on the current state of in vitro display selection of synthetic peptide
binders and compares the selected peptides with natural peptides/proteins to provide a
better understanding of the target affinities and inhibitory activities derived from their amino
acid sequences and structural frameworks. The potential of synthetic peptide binders as
alternatives to antibody drugs in therapeutic applications is also reviewed.
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INTRODUCTION
Since the 1990s, monoclonal antibodies have been developed as
molecular targeting drugs to treat diseases such as cancers and
inflammatory disorders (1, 2). More than 20 antibody drugs (e.g.,
Herceptin for breast cancer and Remicade for rheumatoid arthri-
tis) have been launched to date and are considered perfect agents
with intense pharmacological activities and no side effects. How-
ever, unavoidable issues have been revealed in their development
and prescription (1, 2). For example, chimera antibody drugs that
include part of a mouse antibody are likely to be eliminated by the
human immune system and cause side effects through antibody-
dependent cellular cytotoxicity. Additionally, various patents for
antibody humanization introduce difficulty in some territories for
the production of new antibody drugs. Therefore, the development
of synthetic peptide binders with affinities for a desired target, par-
ticularly those in which peptides are the natural ligands, should
provide an innovative solution to these problems. This mini review
focuses on current studies related to in vitro display technologies
for the selection of synthetic peptide binders and their use in bio-
logical, biotechnological, and medical studies. This also compares
the features of these synthetic peptides with those of natural pep-
tides/proteins to provide an understanding of the relationships
among amino acid sequence, structural conformation, and affin-
ity for a desired target that allow the prediction of their potential
as alternatives to antibody reagents and drugs.
USING PHAGE DISPLAY TECHNOLOGIES TO SELECT PEPTIDE
BINDERS
Many recent studies have been undertaken to develop in vitro
display technologies for the selection of peptide binders from
combinatorial peptide libraries (CPLs). These technologies enable
the creation of new peptides that can bind specifically to a wide
range of target molecules [e.g., receptors, enzymes, viruses, mate-
rials, and small molecules (3–10)]. In particular, such peptides
can be synthesized rapidly and precisely via automated chemi-
cal reactions and modified chemically to expand their functions
and structures. Furthermore, in contrast to antibodies, synthetic
peptides can be stored for long periods in both a solid state and
solution, which facilitates large-scale production at reasonable
costs. Owing to these advantages, synthetic peptide binders have
attracted much attention over the years as alternatives to antibody
reagents and drugs.
During the last decade, phage display has been widely used for
the selection of peptide binders or affinity maturation of anti-
bodies (11–14). By following the scheme (Figure 1A), it becomes
possible to discover unique peptides that dock to the sites of small
molecule-protein interaction, the interfaces of protein–protein
interaction, or the cavities for substrate-enzyme interaction. In
particular, if the binding sites of newly selected peptides on a tar-
get molecule are nearly identical to those of natural ligands, they
can be considered structural or functional mimics. For example,
synthetic peptide binders as mimics of the small molecule“biotin,”
which binds strongly to the tetrameric protein“streptavidin”found
in Streptomyces avidinii, have been selected using phage display
and are well characterized in terms of structural conformation
and target-binding activity at the amino acid sequence level.
The first phage-displayed peptide mimics of biotin were dis-
covered in a 15-mer peptide library of 107, and their amino
acid sequences commonly contain the His-Pro-Gln (HPQ) motif
(15). In another study, this motif was also found in sequences of
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FIGURE 1 | Essential components and schemes for in vitro display
selection. (A) Scheme of phage display selection of peptide binders.
Bacteriophages linking combinatorial peptides as phenotype with their
plasmid DNAs (pDNAs) as genotype are produced in E. coi. A library of
peptides displayed on the pIII coat proteins is panned against target-coated
substrates. Then, target binding phages are selected and their pDNA
sequences are analyzed to identify desirable peptide binders. (B) Upper
panel: DNA constructs used for E. coli ribosome display technology. T7
promoter and RBS are necessary for in vitro transcription and translation,
respectively. The coding sequences for CPL are inserted between suitable
restriction sites and are followed by the coding sequence for FPS. Lower
panel: cycle scheme of E. coli ribosome display selection of peptide
binders. (1) DNA constructs are transcribed in vitro by T7 RNA polymerase
to synthesize mRNAs. (2) The resulting mRNA pool is translated in vitro by a
cell-free protein synthesis system extracted from E. coli to generate a
library of ternary complex that contains CPL, ribosome, and mRNA. Since
each mRNA encodes the sequence of the CPL fused to FPS without stop
codons, which result in stalling of the ribosomes on mRNA,
CPL–ribosome–mRNA complexes can be formed. (3) After mixing the
complexes and target-coated beads/plates, desirable complexes that
display peptides bound to target molecules are selected. (4) The mRNAs are
recovered by dissociation of the selected complexes through the addition of
EDTA. (5) The purified mRNAs are reverse-transcribed in vitro to synthesize
cDNAs, and subsequently amplified by PCR. These resulting DNA
constructs are directly used for the next selection cycle, or are analyzed by
cloning and sequencing to identify new peptide binders. (C) Scheme of
cDNA display selection of peptide binders. (1) The puromycin (p) and biotin
(b) attached DNA linker is ligated with the 3′ end of mRNA encoding
combinatorial peptide. (2) After immobilization of the construct through
binding of biotin to streptavidin-coated surfaces (St-CS), in vitro synthesized
peptide binds to the puromycin and the mRNA is subsequently transcribed
to generate a peptide–cDNA–mRNA complex. (3) Digestion of restriction
sites in the DNA linkers affords a library consisting of peptide–cDNA–mRNA
complexes. (4) Through screen of the library against cells of interest, target
binding complexes are recovered and their cDNA sequences are analyzed
to identify desirable peptide binders.
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selected peptide binders against streptavidin (16). Furthermore,X-
ray crystal structures have revealed that the HPQ motif is located
at the ends of the β-barrels in streptavidin, and that the side chains
of the motif interact with the biotin-binding site (17). Although
the HPQ sequence is indispensable for streptavidin binding affin-
ity and specificity, the dissociation constant, K D, of the peptide
binders was calculated to be in the millimolar range. The affini-
ties of the binders to streptavidin were very low compared to that
of biotin (K D=∼10−15 M). Therefore, to stabilize the structures
of the peptide binders and increase their affinities, libraries of
disulfide-constrained cyclic peptides (CX4C, CX5C, CX6C; C, cys-
teine; X: 20 natural amino acids) were constructed and screened
by phage display (18). The selected cyclic peptide binders had the
HPQ motif and exhibited higher affinities, with K D values in the
nanomolar range, than those of the corresponding linear mole-
cules. In addition, the X-ray crystal structure of a cyclic peptide
bound to streptavidin showed that the interaction of the HPQ
motif with streptavidin is identical to that of the linear peptide
(19). These data demonstrate that the cyclic conformation result-
ing from disulfide bonding increases structural rigidity to decrease
both solvent and peptide entropy, enhancing target affinity.
In a refinement of the cyclization concept, a library of bicyclic
peptides has been synthesized through intramolecular cross-
linking of tris-(bromomethyl)benzene with three cysteine residues
in combinatorial peptide sequences (CX6CX6C) (20). The struc-
turally constrained peptide library was screened against human
plasma kallikrein by using a modified phage display. It is worth
noting that the selected bicyclic peptide exhibited high inhibitory
activity with an inhibition constant (K i) of 1.5 nM, and efficiently
interrupted the intrinsic coagulation pathway in human plasma
ex vivo. Moreover, various chemical approaches for synthesiz-
ing structurally constrained peptides are reported to strengthen
target affinities and provide adequate function (21–23). These
results demonstrate that structurally constrained peptides have
both increased target affinity and proteolytic stability and also
suggest that they are potential new drugs with the advantages of
small molecules and biologics.
Many types of peptide binders have been successfully selected
and used for multiple purposes. However, phage display-derived
peptide binders have often had insufficient affinities against target
molecules because phage display selection has several problems
related to the use of living cells and bacteriophages themselves
(e.g., steric repulsion between target molecules and phage coat
proteins, cell toxicity of peptides, and the use of peptide libraries
of small sizes of 107∼9) (11, 12). These unavoidable phenomena
tend to exclude desired peptide binders from CPLs through selec-
tion. Therefore, to circumvent these limitations and successfully
select peptide binders adapted for wide-ranging uses, it has been
necessary to develop improved display technologies that do not
use living cells.
EMERGENCE OF CELL-FREE DISPLAY TECHNOLOGIES FOR
THE SELECTION OF PEPTIDE BINDERS
Against the above backdrop, ribosome display, mRNA display, and
CIS display have been developed as in vitro, cell free, display tech-
nologies in combination with cell-free protein synthesis systems
(24–26). In selecting peptide binders using these technologies, the
preparation and use of transition complexes that link combinator-
ial peptides (phenotype) and the corresponding mRNAs or DNAs
(genotype) is indispensable. For instance, E. coli ribosome dis-
play selection of peptide binders is generally carried out following
the scheme (Figure 1B). Thus, new peptide binders with affinities
and specificities for a required target can be selected from various
peptide libraries in a small test tube.
Indeed, ribosome (polysome) display has enabled the selec-
tion of decapeptides with high affinities to monoclonal antibody
from a pool of peptide–ribosome–mRNA complexes prepared
from a 1012-member DNA library (27). Interestingly, most of the
selected peptides contain a consensus sequence similar to that of
the known epitope for the target antibody. Moreover, in ribosome
display selection using a 15-mer peptide library of the large size
of 1013 against streptavidin (28), the HPQ sequence essential for
streptavidin binding was found in members of the selected pep-
tides. Furthermore, the peptides and shortened variants possessed
remarkably higher affinities, with K D values in the low nanomolar
range, than those of phage display-derived peptides. In another
case, by screening a library of ribosomal complex stabilized by
automatic association of a protein with an RNA motif at the 5′
terminus of the mRNA, disulfide-constrained peptides with metal
binding affinities were successfully identified even at ambient tem-
perature (29). Moreover, ribosome display can be optimized to
screen not only peptide libraries but also single-chain fragment
variable (scFv) and randomized protein libraries. In fact, in vitro
selection of scFvs and their affinity maturation (30, 31), and explo-
ration of structural proteins with affinities to desired targets (32,
33) have been carried out using improved ribosome display. Ribo-
some display is currently performed with various cell-free protein
synthesis systems derived from eukaryotic cell extracts (34, 35)
and reconstituted completely from the essential elements of 44
E. coli (36). Therefore, the ribosome display selection strategy is
being generalized and applied in a wide range of research and
development fields.
mRNA display selection of peptide binders can be executed
using a scheme similar to that in Figure 1B. However, to link
combinatorial peptides (phenotype) and their mRNAs (geno-
type), covalently linked peptide–mRNA complexes are used for
selection (25). The covalent linkage in the complex is synthe-
sized via reaction of the C-terminus of a nascent polypeptide with
puromycin in the A-site of the ribosome through the formation of
the corresponding peptide–ribosome–mRNA–puromycin com-
plex. In contrast to ribosome display using peptide–ribosome–
mRNA complexes, despite the time and effort required to synthe-
size puromycin-attached mRNAs and validate a purified library of
peptide–mRNA complex, the covalent bonding between combina-
torial peptides and their mRNAs is expected to enable successful
selection of desirable peptide binders from large-size libraries
(1012∼ 14) (37).
For example, in mRNA display selection against calmodulin
(CaM) (38), previously known and novel CaM-binding proteins
with various affinities were identified from a natural protein
library. More than 2000 peptide binders were isolated from a
combinatorial peptide library of ∼1012, some of which had CaM-
binding motifs found in natural proteins. In addition, the selected
peptides bound to CaM tightly, with unique secondary structures
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that differed from the conventional ones. These results imply that
in vitro peptide/protein selection strategy has the potential to dis-
cover unknown protein-peptide/-protein interactions in various
cell-signaling pathways (39, 40). Moreover, the high stability of the
covalently linked peptide–mRNA complexes under physiological
conditions allows their chemical modification through the reac-
tion of functional groups of peptides with organic compounds.
For instance, a hybrid drug-peptide library has been constructed
via reaction of a cysteine side chain in the combinatorial peptide
sequence (X5CX5) with 6-bromoacetyl penicillinate (41). Subse-
quently, the library (∼1012) of synthetic peptides, each bearing
a pendant penicillin moiety, was screened against Staphylococ-
cus aureus penicillin-binding protein 2A (PBP2A). This selection
yielded a novel hybrid penicillin-peptide binder with 100-fold
higher activity than that of penicillin itself. The results indicate that
this approach might be a convenient way to increase the efficiency
of current drugs and create powerful hybrid ligands. Furthermore,
to produce unique peptide inhibitors with proteolytic stability,
an mRNA display library of cyclic peptides was synthesized by
intramolecular cross-linking of disuccinimidyl glutarate with two
primary amines, those of methionine at the N-terminus and a
lysine fixed in the combinatorial peptide sequence (MX10K; M:
methionine, K: lysine) (42). The resulting library was screened
against Gαi1, which is related to G-protein-coupled receptor
(GPCR) signaling. The identified cyclic peptide binder exhibited
strong affinity with K D of ∼2.1 nM, similar to those of mono-
clonal antibodies and higher than that of an endogenous Gαi1
ligand. Additionally, the cyclic structure of the selected peptide
enhanced its resistance to protease degradation compared with
that of the parent linear peptide. Thus, cyclization in the internal
peptide sequence is a useful approach for improving proteolytic
stability and affinity for a desired target.
Currently, a cell-free protein synthesis system can be completely
reconstituted with recombinant elements and purified ribosomes
from E. coli (43) and used to produce proteins/peptides consisting
of not only natural but also unnatural amino acids in combination
with chemically modified amino acyl-tRNAs (44, 45). Reconsti-
tuted ribosomal translational machinery has been used in attempts
to incorporate unnatural amino acids with various functional
groups or backbone structures into combinatorial peptides to gen-
erate unnatural peptide–mRNA libraries. For example, a library of
unnatural cyclic peptides has been constructed through random
incorporation of 12 unnatural amino acids and the reaction of a
dibromoxylene cross-linker with two cysteine residues fixed in the
combinatorial peptide sequence (C(U/X)10C; U, unnatural amino
acids) (46). Subsequently, mRNA display selection using a library
of 1013 highly modified peptides was carried out against throm-
bin as a target molecule. Interestingly, the identified cyclic peptides
possessed unnatural amino acids essential for binding to the target,
and their affinities (K D in the low nanomolar range) were much
higher than those of their linear counterparts. Furthermore, their
high inhibitory activities indicated that unnatural cyclic peptide
binders are a potential new class of drug-like molecules.
Naturally occurring peptides are known to use the cyclic struc-
ture and N -methylated backbone for structural rigidity, specific
target affinity, and proteolytic stability. Synthetic peptides and
mimics with natural peptide-like structures are likely drug-like
molecules with high affinity and specificity against targets in vitro
and in vivo (47–49). Based on this concept, a cell-free protein
synthesis system coupled with various chemically modified amino
acyl-tRNAs has been developed to produce combinatorial peptides
consisting of natural and N -methyl amino acids (N m) (50). Fur-
thermore, chloroacetylated d-amino acid (ClAc) was effectively
introduced at the N-terminus using this system to facilitate inter-
nal cyclization via the reaction of ClAc with a fixed cysteine in the
peptide sequence. Subsequently, a 1012-member mRNA display
library of N -methyl cyclic peptides [ClAc(N m/X)8–15C] was con-
structed through in vitro translation driven by the reconstituted
system and was screened against the E6AP HECT domain (51).
Remarkably, an isolated N -methyl cyclic peptide bound strongly
to the target with a single-digit nanomolar K D and inhibited the
E6AP catalysis of polyubiquitination of proteins such as p53. In
addition, cyclization of all characterized peptides enhanced their
target affinities compared with those of the corresponding lin-
ear peptides. The successful identification and characterization of
natural-like peptide inhibitors indicate that mRNA display selec-
tion would be useful for generating drug-like peptides that can
bridge the gap between small molecule drugs and biologics.
PROSPECTS FOR NEXT-GENERATION PEPTIDE BINDERS AS
MOLECULAR TARGET DRUGS
Previous studies have revealed that in vitro display selection of pep-
tides from a wide variety of libraries is a powerful approach for the
development of synthetic peptide binders against target molecules.
Indeed, various peptide binders have been successfully selected
and used in biology, biotechnology, and biomedical science. Fur-
thermore, characterization of the selected peptides suggests that
synthetic peptide binders might have in vitro molecular target-
ing activities comparable to those of antibodies. Based on these
prospects, modified mRNA display [cDNA display (52)] selection
methods have been developed to produce new peptides that can
bind specifically to GPCRs as major drug targets or to cancer cells
themselves in vivo (Figure 1C).
For instance, as shown in Figure 1C, a library of combi-
natorial peptide (X8)–cDNA–mRNA complexes has been con-
structed (53) and directly screened against growth hormone sec-
retagogue receptors (GHSRs) expressed on CHO cells in culture
medium. The selected peptides exerted an antagonistic effect on
GHSR to suppress the contraction of isolated animal stomach
induced by ghrelin as a natural ligand. In addition, intravenous
administration of these peptides inhibited food intake in mice.
Although the observed inhibitory activity was not as high as that
of present agents, these data contribute to the future development
of anti-obesity peptide drugs.
Conversely, a library of combinatorial peptide (X15)–cDNA–
mRNA complexes has been screened against mammalian cancer
cells under culture conditions (54). Subsequently, a group of pep-
tides binding to cells was collected and re-screened according to
the membrane permeability in a wide variety of cancer cell lines
(HeLa, Lovo, A549, MCF-7, MKN45, HepG2, LNCap, KPK, U2OS,
RC-15, RD-ES, H28, K562, and U251). Some of the final selected
peptides could penetrate only into specific types of primary can-
cer cells of colon adenocarcinoma or acute myelogenous leukemia
(AML). One of these cell-penetrating peptides was fused with the
minimal p16 inhibitory sequence in a type of retro-inverso pep-
tide (55) to induce the apoptosis of target cancer cells in vivo.
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Administration of the fusion peptide to NOD-SCID mice treated
with AML cells or xenografts specifically inhibited tumor metas-
tasis and growth. Therefore, these studies indicate that cell-based
selection using in vitro display technologies have the potential to
discover unprecedented peptide binders with molecular targeting
and inhibitory abilities in vivo.
In conclusion, this review highlights the utility and versatil-
ity of in vitro display technologies for the selection of peptide
binders suitable for multiple purposes in biology, biotechnol-
ogy, and medical science. Furthermore, characterization of the
selected peptides promises that synthetic peptide binders have
potential as molecular target drugs comparable to that of mono-
clonal antibodies. However, to develop peptide-derived drugs that
can be applied in a general medical setting, several issues (poten-
tial immunogenicity, protease degradation, and poor metabolic
stability) remain to be resolved for human administration. There-
fore, establishing an innovative strategy including in vitro display
selection is necessary to discover peptide binders, make chem-
ical modifications to provide protease resistance and metabolic
stability, obtain structural information to optimize target-binding
modes, and perform theoretical simulation to predict dynamic
actions. Such an integrated strategy would facilitate the develop-
ment of next-generation peptide binders and mimics as alterna-
tives to monoclonal antibodies and native ligands, respectively.
The emergence of peptide binders that overcome the above dif-
ficulties will allow us to tailor peptide drugs for the preven-
tion, diagnosis, and treatment of a wide variety of diseases and
cancers.
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